Skip to main content
. 2018 Dec 19;46(5):1063–1072. doi: 10.1007/s00259-018-4236-4

Fig. 3.

Fig. 3

Kaplan-Meier analysis of overall survival in 38 patients with metastatic prostate cancer undergoing 177Lu-PSMA-617 radioligand therapy (RLT). a According to PSA response after RLT: blue line patients with biochemical stable disease (SD) or progressive disease (PD); red line patients with a biochemical partial response (PR) or complete response (CR). b According to total tumor volume (TTV) after RLT: blue line patients with stable disease (SD) or progressive disease (PD); red line patients with a partial response (PR) or complete response (CR)